MBX Biosciences Announces The Completion Of The Last Subject's Last Visit In Its Phase 1 Single And Multiple Ascending Dose Trial Of MBX 1416, The Company's Long-Acting Glucagon-Like Peptide 1 Receptor Antagonist In Development For The Treatment Of...

BenzingaNov 18 08:19 ET

Express News | Mbx Biosciences : Look Forward to Sharing Full-Topline Results of Mbx 1416 Program in Early January 2025

ReutersNov 18 08:03 ET

Express News | Mbx Biosciences Announces Last Subject Last Visit in Phase 1 Trial of Mbx 1416 for the Treatment of Post-Bariatric Hypoglycemia

ReutersNov 18 08:00 ET

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

GlobeNewswireNov 18 08:00 ET

MBX Biosciences | 10-Q: Quarterly report

SECNov 7 08:33 ET · Announcements

MBX Biosciences | 8-K: MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

SECNov 7 08:13 ET